Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + docetaxel versus docetaxel alone for second-line advanced squamous non-small cell lung cancer
ChiCTR1800019638Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Pulmonary squamous cell carcinoma comparing Afatinib + docetaxel with Docetaxel monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
afatinibdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1800019638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019638.